RT Journal Article
SR Electronic
T1 Biweekly Administration of Docetaxel and Gemcitabine as Adjuvant Therapy for Stage II and IIIA Non-small Cell Lung Cancer: A Phase II Study
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 2887
OP 2892
VO 27
IS 4C
A1 KONSTANTINOS N. SYRIGOS
A1 MARIOS KONSTANTINOU
A1 EVANGELLOS SEPSAS
A1 GEORGE PAPAMICHALES
A1 ACHILLEAS LOULLIAS
A1 IONAS BELENIS
A1 IONAS SKOTTIS
A1 ANDRIANI CHARPIDOU
A1 CHARALAMBOS ROUSSOS
YR 2007
UL http://ar.iiarjournals.org/content/27/4C/2887.abstract
AB Background: The aim of this study was to determine the overall survival, progression-free survival, and toxicity associated with adjuvant administration of docetaxel and gemcitabine for completely resected patients with stage II and IIIA non-small cell lung cancer (NSCLC). Patients and Methods: Thirty-nine eligible patients had surgical resection for pathological stage II or IIIA disease and received postoperative gemcitabine 1000 mg/m2 followed by docetaxel 80 mg/m2 on days 1 and 14. Cycles were repeated every 28 days. Results: Treatment compliance was acceptable, at 83%. The median duration of follow-up, time to disease progression, and overall survival was 36.7 months, 17 months and 21 months, respectively. Toxicities were acceptable. Treatment failure revealed brain metastasis (15%), intrathoracic recurrence (24%) and systemic metastasis (36%). Conclusion: The biweekly administration of docetaxel and gemcitabine is a safe, well-tolerated and convenient chemotherapy regimen in the adjuvant setting of completely resected NSCLC stage II and III, with efficacy similar to that reported in other regimens. Hence, this non-platinum based regimen appears promising and warrants further evaluation.